Worse prognosis of local and locally advanced head and neck Merkel cell carcinoma: Is it time to change the treatment paradigm?
Local and locally advanced head and neck MCC carries a significantly worse prognosis compared to MCC at other anatomical sites. Recent evidence of favorable responses to neoadjuvant immunotherapy in MCC, coupled with our findings, suggests that patients with head and neck disease may be appropriate candidates for this novel treatment approach. A paradigm shift toward neoadjuvant immunotherapy, especially for head and neck MCC, warrants serious consideration.
Authors
- T. N. Tairov
- Shlomit Fenig
- Eyal Fenig (ORCID: https://orcid.org/0000-0003-1338-3189)
- Ronen Brenner (ORCID: https://orcid.org/0000-0002-9901-9654)
- А. А. Левко
- Ilia Berezhnov
- Tomer Ziv‐Baran (ORCID: https://orcid.org/0000-0002-2589-8473)
- Alexander Yakobson
- Ina Sarel
- Walid Shalata (ORCID: https://orcid.org/0000-0002-7570-4550)
- Hanna T. Frumin Edri
- Sofiia Turaieva
Institutions
- Ben-Gurion University of the Negev (IL)
- Tel Aviv University (IL)
- Kaplan Medical Center (IL)
- Rabin Medical Center (IL)
- Soroka Medical Center (IL)
- Wolfson Medical Center (IL)
- Alzheimer's Association of Israel (IL)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.3389/fimmu.2025.1691000
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00